phrykt

TriSalus Life Sciences, Inc. (TLSI): who owns it and who trades it

As of Nov 16, 2026, TLSI insiders reported 18 open-market sales worth $140K and 12 purchases worth $3.6M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mary T Szela (CEO), with $79.4K. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling TriSalus Life Sciences

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TLSI

79 funds and institutions reported TLSI shares worth $104M at the end of Q2 2026, about 37% of the company. The largest holder is First Light Asset Management, LLC with 10.7%.

Funds and institutions (13F) 37%Everyone else 63%

10 largest owners, by share of the company

First Light Asset Management, LLC10.7%
BlackRock, Inc.4.3%
Nantahala Capital Management, LLC3.3%
Vanguard Capital Management LLC2.8%
Cerity Partners LLC2.6%
Geode Capital Management, LLC1.9%
Gilder Gagnon Howe & Co LLC1.4%
State Street Corp1.0%
White Pine Capital LLC0.9%
Thompson Siegel & Walmsley LLC0.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
First Light Asset Management, LLC6.55M10.69%$29.8M+29%
BlackRock, Inc.2.66M4.34%$12.1M+77%
Nantahala Capital Management, LLC2.00M3.26%$9.1M-3%
Vanguard Capital Management LLC1.73M2.82%$7.9M+28%
Cerity Partners LLC1.60M2.62%$7.3M+104%
Geode Capital Management, LLC1.19M1.94%$5.4M+53%
Gilder Gagnon Howe & Co LLC850,0811.39%$3.9M-4%
State Street Corp610,9631.00%$2.8M+86%
White Pine Capital LLC547,5770.89%$2.5M+234%
Thompson Siegel & Walmsley LLC536,5340.88%$2.4M-8%
Kennedy Capital Management LLC476,2610.78%$2.2M-2%
Morgan Stanley401,8140.66%$1.8M+2%
Northern Trust Corp379,5720.62%$1.7M+71%
Vanguard Portfolio Management LLC329,4640.54%$1.5M+100%
Vanguard Fiduciary Trust Co320,9560.52%$1.5M+47%
Lionhunter Capital Management, LLC300,2750.49%$1.4MNew
Perkins Capital Management Inc235,1010.38%$1.1M+2%
UBS Group AG223,0470.36%$1M+180%
Bank of America Corp205,3420.33%$934K+2%
Royce & Associates LP200,0600.33%$910KNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TLSI insiders reported $3.6M of open-market purchases and $140K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$3.6M
12 trades, 6 people
Sales, 12 months
$140K
18 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 12, 2026
Filed Nov 16, 2026

Purchases and sales by month

$1.8M$1.8MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 12, 2026Mats WahlstromDirectorPurchase50,000$2.24$112KForm 4
Oct 5, 2026Bryan F. CoxChief of ResearchSale296$4.39$1.3KForm 4
Oct 5, 2026Richard MarshakChief Commercial OfficerSale325$4.39$1.4KForm 4
Oct 5, 2026Jennifer StevensChief Regulatory OfficerSale316$4.39$1.4KForm 4
May 15, 2026Richard MarshakChief Commercial OfficerSale543$2.67$1.4KForm 4
May 15, 2026Mats WahlstromDirectorPurchase60,000$2.53$152KForm 4
May 15, 2026Michael P StanskyDirectorPurchase410,000$2.50$1MForm 4
May 15, 2026Michael P StanskyDirectorPurchase200,000$2.50$500KForm 4
May 15, 2026Mary T SzelaCEOPurchase39,682$2.59$103KForm 4
May 15, 2026David PatienceCFOPurchase7,100$2.43$17.3KForm 4
May 15, 2026Gary B. GordonDirectorPurchase10,000$2.46$24.6KForm 4
Mar 17, 2026Mary T SzelaCEOSale15,944$3.85$61.4KForm 4
Mar 16, 2026Jodi DevlinChief of Clinical OperatSale273$4.12$1.1KForm 4
Mar 16, 2026Bryan F. CoxChief of ResearchSale579$4.12$2.4KForm 4
Mar 16, 2026Richard MarshakChief Commercial OfficerSale419$4.12$1.7KForm 4
Mar 16, 2026Jennifer StevensChief Regulatory OfficerSale774$4.12$3.2KForm 4
Mar 12, 2026Jodi DevlinChief of Clinical OperatSale1,772$4.09$7.2KForm 4
Mar 12, 2026Bryan F. CoxChief of ResearchSale1,467$4.09$6KForm 4
Mar 12, 2026Richard MarshakChief Commercial OfficerSale1,589$4.09$6.5KForm 4
Mar 12, 2026Jennifer StevensChief Regulatory OfficerSale1,552$4.09$6.3KForm 4
Mar 11, 2026Jodi DevlinChief of Clinical OperatSale1,162$4.13$4.8KForm 4
Mar 11, 2026Bryan F. CoxChief of ResearchSale1,138$4.13$4.7KForm 4
Mar 11, 2026Richard MarshakChief Commercial OfficerSale1,449$4.13$6KForm 4
Mar 11, 2026Jennifer StevensChief Regulatory OfficerSale1,204$4.13$5KForm 4
Mar 11, 2026Mary T SzelaCEOSale4,358$4.13$18KForm 4
Feb 23, 2026David PatienceCFOPurchase3,657$4.10$15KForm 4
Feb 23, 2026Gary B. GordonDirectorPurchase9,756$4.10$40KForm 4
Feb 23, 2026William ValleDirectorPurchase30,487$4.10$125KForm 4
Feb 23, 2026Michael P StanskyDirectorPurchase243,900$4.10$1000KForm 4
Feb 23, 2026Michael P StanskyDirectorPurchase117,198$4.10$481KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Michael P StanskyDirector$3M–May 15, 2026
Mats WahlstromDirector$264K–Nov 12, 2026
Mary T SzelaCEO and President, Director$103K$79.4KMay 15, 2026
William ValleDirector$125K–Feb 23, 2026
Gary B. GordonDirector$64.6K–May 15, 2026
David PatienceChief Financial Officer$32.2K–May 15, 2026
Richard MarshakChief Commercial Officer–$17.1KOct 5, 2026
Jennifer StevensChief Regulatory Officer–$15.9KOct 5, 2026
Bryan F. CoxChief of Research–$14.4KOct 5, 2026
Jodi DevlinChief of Clinical Operations–$13.2KMar 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TLSI short interest

Moderate short interest. 5.4% of TLSI shares are sold short: about 1 share in 19. Over the last 12 reports the number of shares short went up 97%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.31M TLSI shares were sold short, 5.4% of the shares outstanding, down 3.8% from the report before. At the average daily volume of 116,423 shares, buying them all back would take about 28.4 trading days (days to cover).

Shares short, % of all shares

5.38%May 15Oct 306.67%

Days to cover

28.4May 15Oct 3041.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.31M5.38%-4%116,42328.4
Oct 15, 20263.44M5.59%+3%171,29220.1
Sep 30, 20263.35M5.44%No change759,5904.4
Sep 15, 20263.35M5.43%-9%116,10728.8
Aug 31, 20263.69M6.00%-3%102,90235.9
Aug 14, 20263.79M6.16%+0%270,68514.0
Jul 31, 20263.77M6.15%+6%170,37022.1
Jul 15, 20263.56M5.81%+16%276,78212.9
Jun 30, 20263.08M5.02%+41%678,9394.5
Jun 15, 20262.19M3.57%+4%323,8796.8
May 29, 20262.10M3.43%+25%428,2374.9
May 15, 20261.69M2.75%+17%1.02M1.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

TriSalus Life Sciences company events

TriSalus Life Sciences filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Sep 22, 2026AnnouncementTriSalus Life Sciences, Inc. issued a press release announcing that it has received U.S. Food and Drug Administration 510(k) clearance for its TriNav Advance device. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. May 14, 2026VoteReported shareholder vote results. Filing
  5. May 12, 2026ResultsReleased financial results. Filing
  6. Apr 29, 2026LeadershipJodi Devlin provided notice to TriSalus Life Sciences, Inc. of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026. Filing
  7. Apr 7, 2026LeadershipTriSalus Life Sciences, Inc. entered into an offer letter with Dr. Richard Marshall for the position of Chief Medical Officer. Filing
  8. Mar 5, 2026ResultsReleased financial results. Filing
  9. Feb 20, 2026AgreementTriSalus Life Sciences, Inc. entered into an underwriting agreement with Lake Street Capital Markets, LLC, as representative of the underwriters named therein, relating to the public offering of 9,756,100 shares of common stock of the Company, par value $0.0001 per share, at a price to the public… Filing
  10. Feb 9, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Directors; Compensatory Arrangements of Certain Officers. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

TriSalus Life Sciences financials

Famous investors that hold TLSI

1 of the 50 well-known investors we track reported holding TLSI in their latest 13F filing. The largest position is Israel Englander's, worth $156K.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 202636,140$156K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TLSI in the last 120 days.

FiledHolderFormStake
Nov 16, 2026First Light Asset Management, LLC13G/A12.0%
Nov 16, 2026First Light Asset Management, LLC13G/A12.0%

Questions about TriSalus Life Sciences, Inc. (TLSI) stock

Who owns the most TLSI stock?

The largest reported owner of TriSalus Life Sciences, Inc. (TLSI) is First Light Asset Management, LLC, with 10.7% of the company. In total, 79 funds and institutions reported holding TLSI at the end of Q2 2026, together about 37% of the shares. See the largest owners.

Are TLSI insiders buying or selling?

In the last 12 months, TLSI insiders reported 12 open-market purchases worth $3.6M and 18 sales worth $140K. The latest trade was on Nov 12, 2026. See every trade.

What is the short interest in TLSI?

As of Oct 30, 2026, 3.31M TLSI shares were sold short, 5.4% of the shares outstanding, down 3.8% from the report before. At the average daily volume of 116,423 shares, buying them all back would take about 28.4 trading days (days to cover). See the history.

Which famous investors hold TLSI?

1 of the 50 well-known investors we track reported TLSI in their latest 13F filing, including Israel Englander. The largest position is worth $156K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.